Activator of small conductance Ca2+-activated K+ channels that displays selectivity for KCa2.2 (SK2) and KCa2.3 (SK3) channels (EC50 values are 5.6 and 14 μM for KCa2.3 and KCa2.2 respectively). Displays no activity at KCa2.1 (SK1) and KCa3.1 (IK) channels.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Hougaard et al (2007) Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br.J.Pharmacol. 151 655 PMID: 17486140
If you know of a relevant reference for CyPPA, please let us know.
View Related Products by Product Action
Keywords: CyPPA, CyPPA supplier, activators, SK2, SK3, channels, Potassium, KCa, KCa2.2, KCa2.3, Channels, ca2+-activated, ca2+-dependent, K+, SKCa2, SKCa3, Ca2+-Activated, 2953, Tocris Bioscience
2 Citations for CyPPA
Citations are publications that use Tocris products. Selected citations for CyPPA include:
Abdulkareem et al (2016) Knockdown of the small conductance Ca(2+) -activated K(+) channels is potently cytotoxic in breast cancer cell lines. J Exp Clin Cancer Res 173 177 PMID: 26454020
Benton et al (2013) Iberiotoxin-sensitive and -insensitive BK currents in Purkinje neuron somata. J Neurophysiol 109 2528 PMID: 23446695
Do you know of a great paper that uses CyPPA from Tocris? Please let us know.
Reviews for CyPPA
There are currently no reviews for this product. Be the first to review CyPPA and earn rewards!
Have you used CyPPA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.